Mechanism of Remazolam's Effect on Liver Cell Function of Cirrhosis Group by Regulating CES1 Gene Expression in Painless Gastrointestinal Endoscopy

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100045829

Enrollment

Unknown

Registered

2021-04-25

Start date

2021-06-01

Completion date

Unknown

Last updated

2021-12-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocirrhosis

Interventions

control group:Conventional sedation anesthesia

control group (Cirrhosis):Conventional sedation anesthesia

experimental group (Cirrhosis):Remazolam

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged 45-55 years, ASA classification III and below, BMI range 18-25; 2. No serious cardiovascular and cerebrovascular system diseases, no records of cognitive dysfunction and other mental diseases, no active bleeding and severe coagulation dysfunction, no blood system diseases, no drug dependence, no allergies to any of the drugs in this study, Perform gastrointestinal endoscopy ERCP treatment; 3. Those who know and agree to participate in this trial.

Exclusion criteria

Exclusion criteria: Other adverse events.

Design outcomes

Primary

Measure	Time frame
hepatic function;Awakening time;	—

Countries

China

Contacts

Public ContactLi Wei

Shandong Provincial Hospital Affiliated to Shandong First Medical University

mazuiliwei@163.com+86 18753157679

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026